Navigation Links
International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
Date:1/28/2009

produce antibodies and are a specialised form of B-lymphocyte. In myeloma a single cell becomes malignant and produces a very large number of identical cells (a clone). In normal circumstances, the antibody molecules present in the blood are very varied in their structure, reflecting the large number of infections they may be required to combat. In patients with myeloma very large quantities of a single type of antibody are produced. This is called a paraprotein and it is present in the blood and/or urine in about 99% of cases. Normal antibody levels are almost always reduced in myeloma. This, combined with a slight reduction in numbers of neutrophils, leads to a susceptibility to infections which may be life-threatening. When there is no detectable paraprotein it is called non-secretory myeloma. Detection of a paraprotein is not sufficient to give a diagnosis of multiple myeloma, as this may also occur in other conditions including lymphoma, MGUS, amyloidosis and some inflammatory disorders. Source: http://www.lrf.org.uk/en/1/infdispatmul.html.

About AL amyloidosis

AL amyloidosis used to be called 'primary systemic amyloidosis' and is now the most commonly diagnosed form of the disease. Patients with AL amyloidosis have an abnormal line of cells (called plasma or B cells) which are usually in the bone marrow, and which produce the amyloid forming protein. The AL amyloid forming protein is part of a protein called monoclonal immunoglobulin; the part that forms AL amyloid is called the light chain. Abnormal free light chains can be measured in the blood in about 95% of patients with AL amyloidosis. The underlying bone marrow disorder/monoclonal immunoglobulin producing disorder is known by many different names (plasma cell disorder, plasma cell dyscrasia, paraprotein disorder, monoclonal gammopathy, etc), and is very subtle in 80% of patients.
'/>"/>

SOURCE The Binding Site Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LONDON , March 27, 2015 ... Royal Free Hospital in London , Richmond ... for a global Phase 3 study for an investigational RNAi ... an orphan disease affecting the nerves and heart. ... Record Detail Based at St Georges University ...
(Date:3/27/2015)... Governor Andrew M. Cuomo today announced ... - the world’s largest business idea competition with $5 ... $1 million, six $500,000 awards and four $250,000 awards. ... compete for prizes that will turn ideas with high ... York region. , "Last year's successful 43North competition ...
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
Breaking Biology Technology:Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5SQI Diagnostics Inc. Announces Adjournment of Meeting 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... - Asian populations with regard to risk associated in the ... osteoporosis or cardiovascular disease, ... in response to nutritional ... WALTHAM, Mass., Feb. 28 Interleukin Genetics,Inc. (Amex: ILI ...
... Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, What: ... Conference Call, When: ... http://www.transgenomic.com/events.asp?id=6 , How: ... address above., ...
... ANDS ) today announced that patient dosing has ... oral TLR7 agonist prodrug, in,patients with advanced solid tumors. ... to identify pharmacologically active doses,and preliminary antitumor activity as ... II trials., The Phase I trial is a ...
Cached Biology Technology:Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 2Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 3Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 4Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)... --  Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... (March 30, 2011)The Society of Interventional Radiology Foundation,s Discovery ... invasive medicine into new areas of discovery, announced a ... provider of medical devices for vascular access and the ... in Marlborough, Mass., has pledged $500,000 and was named ...
... German . , Innovations relating to mobility, energy, ... at the 2011 Hannover Messe from April 4 8. ... a hybrid Porsche racing car, developments in battery research, materials ... European energy supply system, and the Energy Solution Center (EnSoC) ...
... blood be the key to creating cyborg interfaces? Circuitry that ... device, such as a robotic limb or artificial eye might ... components. Writing in the International Journal of Medical ... a "memristor" can be made using human blood. Memristors were ...
Cached Biology News:Fueling interventional radiology growth: SIR Foundation announces Navilyst Medical Pledge 2KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5Blood simple circuitry for cyborgs 2
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
... 2000 One-Step FP Standardization Kit is ... low fluorescence polarization values of fluorescein ... Beacon 2000 System. It also allows ... generated by their instrument to the ...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Biology Products: